Clinical Trial Overview

This trial is a sponsor‑initiated Phase 1b study by Cellzin, designed to add iberdomide (CC-220) and CC-99282 to the standard R-CHOP regimen. The study started in September 2021, is currently enrolling, and the primary objective is to assess safety and preliminary efficacy.

Study Design and Phases

The study consists of two parts. In Part 1, dose escalation is performed with two parallel arms that combine either CC-220 or CC-99282 with R-CHOP. Part 2 proceeds to a randomized dose‑expansion cohort using the recommended Phase 2 dose (RP2D) defined in Part 1; once the RP2D is confirmed, an additional cohort combining polarizumab‑CHP will be explored.

Patient Population and Current Treatment Landscape

The primary population is patients with activated B‑cell lymphoma (a‑BCL). The current first‑line standard of care is R-CHOP, yet relapse and refractory rates remain high.

Differentiation and Mechanism of Action

Iberdomide is a cereblon‑based E3 ligase modulator that suppresses immune evasion and enhances immune cell activity. CC-99282 has not been fully disclosed but is designed to synergize with R-CHOP.

Timeline and Expected Impact

The trial is in the enrollment phase, with first safety data anticipated by the end of 2023. Positive Phase 1b results would support a larger Phase 2 expansion and could lay the groundwork for shifting the treatment paradigm for a‑BCL lymphoma.